Eli Lilly hiked its 2025 guidance and posted second-quarter revenues that topped quotes on strong need for its blockbuster weight reduction and diabetes drugs.
Source
Related Articles
Eli Lilly hikes 2025 outlook, tops quarterly quotes as Mounjaro, Zepbound sales soar